barrett-s-esophagus | Media Room

Press Release Feb 1, 2022

Symple Surgical Awarded SBIR Phase I Grant for Novel Radiometry‐Guided Ablation Catheter to Reliably Treat Barrett's Esophagus

The National Institutes of Health Small Business Innovation Research Program Supports Symple Surgical's Microwave Ablation Technology

Press Release Sep 10, 2020

Cernostics and Deciphex Announce Strategic Collaboration to Develop AI-Based Histology Diagnostics and Prognostics for Barrett's Esophagus

By combining Deciphex's unique digital pathology solutions with Cernostics tissue systems pathology approach, the partnership aims to generate novel predictive indicators using AI.

Press Release Sep 1, 2020

Aqua Medical Announces Final $8.2 Million Equity Investment Led by ShangBay Capital to Close Its $15.5 Million Series A Financing Round

Investment will be used to advance its novel vapor-based ablation system to treat precancerous conditions and metabolic disease such as type 2 diabetes in the gastrointestinal (GI) tract.

Press Release Jun 25, 2020

Cernostics Announces Blinded, Independent Validation of TissueCypher(R) Performance for Predicting Risk of Progression to Esophageal Cancer in Patients With Non-Dysplastic BE

Study further validates TissueCypher(R) as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma

Press Release Mar 3, 2020

Cernostics Announces Groundbreaking Data Demonstrating TissueCypher Performance for Predicting Risk of Progression to EAC in Patients With Non-Dysplastic BE

First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high-risk, non-dysplastic BE patients that progress to EAC at rates higher than expert-confirmed LGD

Press Release Oct 22, 2019

TissueCypher® Further Validated to Accurately Risk Stratify Barrett's Esophagus Patients With Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the fourth independent validation of TissueCypher performance for risk stratifying non-dysplastic Barrett's esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD)